After graduating from Manchester University with a degree in Biochemistry Kevin spent 6 years working in a clinical histopathology laboratory at the Queen’s Medical Centre, Nottingham, where he achieved State Registration as a Biomedical Scientist.
In 1997, shortly after gaining a Masters degree in Biomedical Sciences from Nottingham Trent University, he moved to AstraZeneca at Alderley Park to join Safety Assessment. During his 17 years at AZ Kevin lead a small team developing, validating and applying tissue-based assays in drug discovery, preclinical safety assessment and translational medicine.
After leaving AZ, Kevin spent 4 years with Hematogenix, a Chicago-based CRO, establishing and managing their European CAP/CLIA accredited histology/molecular pathology facility.
In February 2019 Kevin joined Medicines Discovery Catapult and has built a Molecular Pathology capability in support of in-house projects and providing access to state-of-the-art molecular pathology facilities and expertise for UK-based biotech, pharma and CROs.
Kevin has extensive experience in histology, immunohistochemistry, in situ hybridisation, image analysis and electron microscopy, and has authored/co-authored many peer-reviewed publications.